Clearmind Medicine Inc. CMND
5.09 USD -0.41 (-7.45%)
At closeNov 10, 2026, 4:00 PM EST
5.39 +0.30 +5.89%
After hours · Nov 10, 4:00 PM ET
5.09 Day range 5.76
5.09 52-week range 2,172.80
- YTD
- -96.48%
- 1 year
- -99.77%
News
globenewswire.com Clearmind Medicine Among Top Biopharma Companies Invited to join Washington DC, Psychedelic Summit Vancouver, Canada, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity…
benzinga.com Clearmind Medicine Completes Participant Recruitment For First Segment Of Part B Of Its Phase I/IIa Clinical Study Of CMND-100 To Treat Alcohol Use Disorder Clearmind Medicine Inc. (Nasdaq: CMND) ("Clearmind" or the "Company"), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable…
globenewswire.com Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial Milestone advances Clearmind's clinical program as the company continues to develop CMND‑100 as a potential novel therapeutic candidate for alcohol use disorder
benzinga.com Clearmind Medicine's Charging Robotics Subsidiary Rolls Out Autonomous Vehicle Charging Platform Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation
globenewswire.com Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets Vancouver, Canada, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development…
benzinga.com Clearmind Medicine Publishes Patient Application In Japan For Its Compositions And Methods For Treating Dyskinesia Clearmind Medicine Inc. (Nasdaq: CMND) (the "Company"), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of…
globenewswire.com Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder Published patent application covers 3-MMC-based treatment of dyskinesia, including in combination with Palmitoylethanolamide (PEA) Vancouver, Canada, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Clearmind…
globenewswire.com Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA Company Calls for Consideration of New Regulatory Pathways and Cost Saving of Non-Hallucinogenic Neuroplastogens for Alcohol Use Disorder
benzinga.com Clearmind Medicine Announces 1-For-8 Reverse Share Split, Effective October 5, 2026 learmind Medicine Inc. (the "Company") is announcing that it will effect a reverse share split of the Company’s common shares at the ratio of 1-for-8, such that each eight (8) common shares, no par…
thenewswire.com NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations The U.S. patent applications cover proprietary combinations of NeuroThera's PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders,…
benzinga.com Clearmind Medicine Announces Three U.S. Patent Applications Covering Novel Proprietary Combinations Of LSD, Ketamine And Ibogaine With N-Acylethanolamines Such As Palmitoylethanolamide The covered applications address potential therapeutic uses across a range of indications, including mental health disorders, such as depression, post-traumatic stress disorder ("PTSD"), pain and…
globenewswire.com Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations The covered applications address potential therapeutic uses across a range of indications, including mental health disorders, such as depression and PTSD as well as substance use disorders
thenewswire.com Stickit Technologies Announces Corporate Update: Leadership Appointments, Capital Restructuring & Loan Acquisition, And Update Of Intellectual Property Portfolio VANCOUVER, BC September 17, 2026 - TheNewswire — StickIt Technologies Inc. (CSE: STKT) (the "Company" or "StickIt"), a developer and patent holder of proprietary cannabinoid and plant extract…
globenewswire.com Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C. Mary-Elizabeth Gifford, Chief of Global Impact at Clearmind Medicine, spoke on patient access and shared insights from Clearmind's clinical trial at Yale and Johns Hopkins
globenewswire.com Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial Vancouver, Canada, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic…
benzinga.com Clearmind Medicine Says Yale University’s IRB Approves Initiation Of Patient Recruitment For Parts B And C Of Phase I/II Clinical Trial Evaluating CMND‑100 Clearmind Medicine Inc. (NASDAQ:CMND) (the "Company" or "Clearmind"), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment…
globenewswire.com Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results Vancouver, Canada, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company” or “Clearmind”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers iSpecimen (NASDAQ:ISPC) shares increased by 10.4% to $1.7 during Friday's after-market session. The market value of their outstanding shares is at $3.8 million. Genelux (NASDAQ:GNLX) stock…- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Immuron (NASDAQ:IMRN) shares moved upwards by 48.2% to $1.65 during Friday's regular session. The market value of their outstanding shares is at $8.9 million. bioAffinity Technologies…
benzinga.com Clearmind Medicine Stock Slides Friday: What's Happening? Shares of Clearmind Medicine Inc. (NASDAQ:CMND) are trading lower Friday morning as investors digest news of the clinical-stage biotech company expanding beyond its core pharmaceutical focus to…
benzinga.com Clearmind Medicine Stock Slides Friday: What's Happening? Clearmind Medicine shares are trading lower Friday as investors weigh the biotech’s move to acquire a majority stake in an EV charging firm.
globenewswire.com Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis Charging Robotics is one of the few worldwide developing innovative wireless charging systems designed specifically for automated parking facilities and autonomous mobile platforms- environments…- benzinga.com Clearmind Medicine Initiates Phase lla, Double-Blind, Placebo-Controlled Phase I/IIa Clinical Trial Evaluating CMND-100 For Treatment Of AUD Clearmind Medicine Inc. (NASDAQ:CMND) (the "Company"), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of…
globenewswire.com Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled Vancouver, Canada, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic…- benzinga.com SciSparc Unit Neurothera Labs And Clearmind Medicine Publish U.S. Patent Application For A Novel Combination Of 3,4-Methylenedioxymethamphetamine And N-Acylethanolamines For Use In Methods Of Treating Post-Traumatic Stress Disorder, Anxiety And Eating Disorders SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that its subsidiary, NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on
- benzinga.com Clearmind Medicine Advances Its IP Portfolio With Publication In U.S. Of Its Patent Application For Novel Combination Of 3,4-Methylenedioxymethamphetamine And N-Acylethanolamines To Treat Post-Traumatic Stress Disorder Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage biopharmaceutical company advancing non-hallucinogenic, psychedelic-derived neuroplastogens for scalable treatment of neuropsychiatric,…
globenewswire.com Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation U.S. publication of the patent application covering the MDMA-N-acylethanolamines combination expands intellectual property generated through the collaboration with Neurothera Labs Inc. as the FDA…
thenewswire.com NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation U.S. publication of a patent application covering the MDMA-N-acylethanolamines combination expands intellectual property generated through the collaboration, and provides guidance addressing clinical…
benzinga.com Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial The independent Data and Safety Monitoring Board on Thursday unanimously approved Clearmind Medicine Inc. (NASDAQ:CMND) to advance its ongoing FDA-regulated Phase 1/2 clinical trial.
benzinga.com Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial Clearmind Medicine advances the CMND-100 clinical trial for alcohol use disorder to Parts B and C following positive Phase A safety data.
globenewswire.com Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint Clearmind Medicine has received Independent Data and Safety Monitoring Board (DSMB) approval to advance its clinical evaluation of CMND ‑ 100 in patients with Alcohol Use Disorder (AUD) - a key…
globenewswire.com Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug Delivery Vancouver, Canada, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND, FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and…
globenewswire.com Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study Clearmind Medicine has received Independent Data and Safety Monitoring Board (DSMB) approval to advance its clinical evaluation of CMND‑100 in patients with Alcohol Use Disorder (AUD) - a key…- benzinga.com Clearmind Medicine Announces Safety Results From Part A Of Its Ongoing FDA-regulated Phase I/II Clinical Trial Evaluating CMND-100; All 24 Participants Enrolled Across Four Ascending-Dose Cohorts Successfully Completed Treatment Completed treatment as planned per-protocol, reinforcing the strength of its proprietary drug candidate, CMND-100. The study achieved its primary endpoint of safety and tolerability. CMND-100…
- benzinga.com Clearmind Medicine Completes Treatment For All Participants In Part A Of Its Ongoing Phase I/II Clinical Trial Evaluating CMND-100 For Alcohol Use Disorder All 24 participants across cohorts 1 through 4 have successfully completed treatment according to the study protocol.The Company is currently assessing the dataset and, assuming results remain…
- benzinga.com Clearmind Medicine Files Hong Kong Patent Application For Innovative Psychedelic Compounds For Treatment Of Post-Traumatic Stress Disorder The Hong Kong patent application forms part of Clearmind’s exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem ("Yissum"). Under the…
benzinga.com Clearmind Medicine Announces Ex Vivo Mucoadhesion Results For Intranasal MEAI; New Formulation Demonstrated Markedly Improved Nasal Residence Characteristics Compared With Standard MEAI Solution Enhanced nasal retention is a critical step toward maximizing MEAI absorption and therapeutic potential. These results reinforce Clearmind’s strategy of developing differentiated, next‑generation…
benzinga.com Clearmind Medicine Announces CMND‑100, Current Phase I/IIa Trial Demonstrates Impression To Treat Alcohol Use Disorder Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,
benzinga.com Clearmind Medicine Files Response To U.S. Department Of Health And Human Services Request For Information About MEAI's Potential To Treat Addiction Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage a biotech company developing novel, non-hallucinogenic, next-generation, neuroplastogen-derived therapeutics to solve major under-treated…- benzinga.com Clearmind Medicine Announces Progress In Evaluating Intranasal Delivery Of Its Proprietary MEAI Treatment For Alcohol Use Disorder The program is evaluating intranasal delivery of MEAI as a potential additional route of administration, with initial studies focused on assessing formulation feasibility and supporting the continued…
- benzinga.com Clearmind Medicine Granted Additional US Patent Titled BINGE BEHAVIOR REGULATORS By USPTO Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,
- benzinga.com Clearmind Medicine Completes Treatment For All Participants In Part A Of Ongoing Phase I/II Clinical Trial Evaluating CMND-100 For Treatment Of Alcohol Use Disorder Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,
- benzinga.com UPDATE: Clearmind Medicine Secures U.S. Patent Covering MEAI-Based Compositions And Methods For Regulating Binge Drinking, Eating, And Gambling Behaviors Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,…
- benzinga.com Clearmind Medicine Completes Dosing Of All 24 Participants In Groups 1 To 4 Of Part A Of Its Phase I/II Clinical Study Of CMND-100 To Treat Alcohol Use Disorder Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Clearmind Medicine To Host June 10 Webinar On The Latest Clinical Data From Its Phase I/IIa Trial Evaluating CMND-100 Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,…